AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

AbbVie (ABBV) announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Published first on TheFly – the ...

(RTTNews) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...